Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Wuxi Biologics (Cayman) (HK:2269)
:2269
Holding HK:2269?
Track your performance easily
2269 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$10.14 - HK$32.25
Previous CloseN/A
Volume35.71M
Average Volume (3M)46.77M
Market Cap
HK$72.84B
Enterprise ValueHK$48.05B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)26.3
Beta1.67
Next Earnings
Mar 25, 2025EPS Estimate
0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.68
Shares Outstanding4,106,229,500
10 Day Avg. Volume41,942,241
30 Day Avg. Volume46,773,398
Standard Deviation0.17
R-Squared0.42
Alpha0.00896
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)14.68
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$3.28Price Target Upside-81.74% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Wuxi Biologics (Cayman) News
PremiumCompany Announcements
WuXi Biologics Announces Hong Kong Office Relocation
PremiumCompany Announcements
Wuxi Biologics Sells Vaccines Ireland Facility for $500M
PremiumCompany Announcements
WuXi Biologics Welcomes New Non-Executive Director
PremiumCompany Announcements
WuXi Biologics Updates Board and Committees
PremiumCompany Announcements
WuXi Biologics Responds to U.S. House Draft BillBulls Say, Bears Say
Bulls Say
Global Market PositionWuXi Biologics is a leading player in the biologics CXO market, holding a 13% global market share and a dominant position in China.
Project ExpansionWuXi Bio added 151 new projects in 2024, the highest number in its history.
Revenue GrowthManagement reaffirmed its 2024 guidance, projecting 5–10% growth in both revenue and adjusted profit, while expressing confidence that revenue growth will accelerate in 2025.
Bears Say
Market SentimentDespite strong demand for antibody-drug conjugates, the potential passing of the Biosecure Act is causing negative market sentiment, leading to a decline in share prices for Chinese CXOs.
Political UncertaintyThere is a higher likelihood of the Biosecure Act being implemented due to a shift in political power, which adds uncertainty to WuXi Biologics' future operations in the US market.
Regulatory RiskThe Biosecure Act poses a significant threat to WuXi Biologics as it could ban US companies from dealing with the firm, affecting over half of its business.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
5.68% Mutual Funds
0.02% Other Institutional Investors
87.55% Public Companies and
Individual Investors
2269 FAQ
What was Wuxi Biologics (Cayman) ’s price range in the past 12 months?
Wuxi Biologics (Cayman) lowest stock price was HK$10.14 and its highest was HK$32.25 in the past 12 months.
What is Wuxi Biologics (Cayman) ’s market cap?
Wuxi Biologics (Cayman) ’s market cap is HK$72.84B.
When is Wuxi Biologics (Cayman) ’s upcoming earnings report date?
Wuxi Biologics (Cayman) ’s upcoming earnings report date is Mar 25, 2025 which is in 65 days.
How were Wuxi Biologics (Cayman) ’s earnings last quarter?
Wuxi Biologics (Cayman) released its earnings results on Aug 21, 2024. The company reported HK$0.372 earnings per share for the quarter, missing the consensus estimate of HK$0.436 by -HK$0.064.
Is Wuxi Biologics (Cayman) overvalued?
According to Wall Street analysts Wuxi Biologics (Cayman) ’s price is currently Overvalued.
Does Wuxi Biologics (Cayman) pay dividends?
Wuxi Biologics (Cayman) does not currently pay dividends.
What is Wuxi Biologics (Cayman) ’s EPS estimate?
Wuxi Biologics (Cayman) ’s EPS estimate is 0.46.
How many shares outstanding does Wuxi Biologics (Cayman) have?
Wuxi Biologics (Cayman) has 4,106,229,500 shares outstanding.
What happened to Wuxi Biologics (Cayman) ’s price movement after its last earnings report?
Wuxi Biologics (Cayman) reported an EPS of HK$0.372 in its last earnings report, missing expectations of HK$0.436. Following the earnings report the stock price went down -2.906%.
Which hedge fund is a major shareholder of Wuxi Biologics (Cayman) ?
Currently, no hedge funds are holding shares in HK:2269
---
Wuxi Biologics (Cayman) Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$3.28 (-81.74% Downside)
HK$3.28 (-81.74% Downside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-39.97%
12-Months-Change
Fundamentals
Return on Equity
6.75%
Trailing 12-Months
Asset Growth
7.57%
Trailing 12-Months
Company Description
Wuxi Biologics (Cayman)
Wuxi Biologics (Cayman), Inc. is an investment holding company, which engages in the discovery, development and manufacture of biologics services. Its services include testing; clinical drug substance cGMP manufacture; commercial drug substance cGMP manufacture; drug product cGMP fill and finish; antibody drug conjugates; regulatory affairs; and technologies and platforms. The company was founded on May 24, 2010 and is headquartered in Wuxi, China.
---
2269 Company Deck
---
2269 Earnings Call
Q2 2024
0:00 / 0:00
---
2269 Stock 12 Month Forecast
Average Price Target
HK$3.28
▼(-81.74% Downside)
Technical Analysis
Wuxi Biologics (Cayman)
―
BeiGene
―
Zai Lab
―
I-MAB
―
HUTCHMED
―
Alnylam Pharma
―
Sangamo Biosciences
―
Best Analysts Covering 2269
1 Year
1 Year Success Rate
2/4 ratings generated profit
1 Year Average Return
+13.88%
reiterated a buy rating 5 months ago
Copying Jialin Zhang's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +13.88% per trade.
---